Abstract
Angiogenesis inhibitors (AIs) such as bevacizumab (BEV) and ramucirumab (RAM) plays an important role in the treatment of metastatic colorectal cancer (mCRC). Although BEV blocks circulating VEGF-A, RAM is an anti-VEGF receptor 2 antibody which prevents ligands (VEGF-A, C, and D) binding. AIs can cause renal adverse events (AEs) including proteinuria and nephrotic syndrome, but little is known about whether previous therapy affects renal AEs. The purpose of this study is to evaluate the association between BEV-induced proteinuria and history of RAM in mCRC patients (pts).
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call